Novocure price target lowered to $102 from $104 at Wells Fargo

Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Novocure to $102 from $104 and keeps an Overweight rating on the shares. Novocure reported mixed Q2 results, with TRx and active patient volumes generally better than expected, the analyst tells investors in a research note.